Valo Health Appoints Chris Anagnostopoulos, PhD, as Chief Causal AI Officer

Lex­ing­ton, MA, April 14, 2026 — Valo Health, Inc. (“Valo”), a pio­neer in the use of human data and AI to accel­er­ate drug dis­cov­ery and devel­op­ment, today announced the appoint­ment of Chris Anag­nos­topou­los, PhD, C.Stat, to the new­ly cre­at­ed posi­tion of Chief Causal AI Offi­cer. In this role, Dr. Anag­nos­topou­los will lead the advance­ment of Valo’s human causal biol­o­gy plat­form, trans­lat­ing large-scale, real‑world human data into causal insights that inform drug discovery. 

Valo aims to improve clin­i­cal suc­cess rates by refin­ing how dis­eases are clas­si­fied, uncov­er­ing causal dri­vers ear­li­er in drug dis­cov­ery, and devel­op­ing nov­el ther­a­peu­tics for spe­cif­ic patient groups. The com­pa­ny has unique access to lon­gi­tu­di­nal real-world data from more than 20 mil­lion patients, includ­ing records span­ning 20 – 30 years and linked genom­ic infor­ma­tion. Valo uses AI/ML to iden­ti­fy patient sub­types in this real-world data, and advanced causal infer­ence tech­niques to infer the causal dri­vers of dis­ease, and how to inter­vene. These human-val­i­dat­ed causal insights then feed direct­ly into Valo’s pre­dic­tive chem­istry plat­form, enabling the rapid devel­op­ment of nov­el ther­a­peu­tics ground­ed in human biol­o­gy and designed for clin­i­cal success. 

“The cre­ation of this posi­tion and strate­gic appoint­ment under­score the impor­tance we place on human causal evi­dence as the foun­da­tion of drug dis­cov­ery, and the oppor­tu­ni­ty we see for causal AI/ML tools to help solve the trans­la­tion­al gap,” said Bri­an Alexan­der, MD, MPH, CEO of Valo Health. ​“Dr. Anag­nos­topou­los brings an excep­tion­al­ly rare skill set at the inter­sec­tion of AI, sta­tis­tics, and human biol­o­gy. His exper­tise will be instru­men­tal as we con­tin­ue scal­ing this capa­bil­i­ty, enabling a new era of drug dis­cov­ery that is anchored in human causal biology.”

Dr. Anag­nos­topou­los is a sea­soned AI and life sci­ences inno­va­tion leader with more than two decades of expe­ri­ence span­ning acad­e­mia, glob­al con­sult­ing, tech­nol­o­gy star­tups, and lead­ing bio­phar­ma­ceu­ti­cal com­pa­nies. He joins Valo from Quan­tum­Black, AI by McK­in­sey, where he served as Tech Fel­low Part­ner, Glob­al Direc­tor of AI Inno­va­tion in Life Sci­ences, and co‑founder of McKinsey’s Sci­en­tif­ic AI ser­vice line, dri­ving the appli­ca­tion of causal machine learn­ing and advanced ana­lyt­ics across bio­phar­ma R&D. Pre­vi­ous­ly, Dr. Anag­nos­topou­los held senior lead­er­ship roles at the tech­nol­o­gy uni­corn Improb­a­ble and was also an Asso­ciate Pro­fes­sor at Impe­r­i­al Col­lege London. 

“Drug dis­cov­ery is strug­gling with a widen­ing clin­i­cal trans­la­tion gap, which con­sis­tent­ly dri­ves low clin­i­cal tri­al suc­cess rates, despite a grow­ing num­ber of drug can­di­dates,” said Dr. Anag­nos­topou­los. ​“Address­ing this causal gap requires inte­grat­ing human causal biol­o­gy insights as ear­ly as pos­si­ble in drug dis­cov­ery. Valo’s plat­form rep­re­sents a tru­ly dif­fer­en­ti­at­ed way to do this, extract­ing causal mech­a­nisms of dis­ease from deep human data. I’m thrilled to join this tal­ent­ed team and work togeth­er to ful­ly lever­age causal AI to advance human health.” 

Dr. Anag­nos­topou­los was a Research Fel­low in the pres­ti­gious Sta­tis­ti­cal Lab­o­ra­to­ry at Cam­bridge Uni­ver­si­ty, and holds a PhD in Sta­tis­tics from Impe­r­i­al Col­lege Lon­don, as well as two MSc degrees, one in Machine Learn­ing from the Uni­ver­si­ty of Edin­burgh, and one in The­o­ret­i­cal Com­put­er Sci­ence from the Uni­ver­si­ty of Athens. He earned his under­grad­u­ate degree in Math­e­mat­ics at Cam­bridge Uni­ver­si­ty. He is a Char­tered Sta­tis­ti­cian (C.Stat) of the Roy­al Sta­tis­ti­cal Soci­ety and cur­rent­ly serves as an Hon­orary Asso­ciate Pro­fes­sor at Impe­r­i­al Col­lege Lon­don.
 

About Valo Health:
Valo is redefin­ing drug dis­cov­ery and devel­op­ment through its AI-enabled human causal biol­o­gy and closed loop chem­istry plat­forms. Valo uses AI to under­stand dis­ease causal­i­ty, iden­ti­fy patient sub­types across het­ero­ge­neous dis­eases, and pin­point nov­el drug tar­gets. The Com­pa­ny val­i­dates tar­gets using pro­pri­etary 3D engi­neered human tis­sue mod­els that mim­ic mature human phys­i­ol­o­gy and struc­ture. The Company’s closed loop chem­istry plat­form enables rapid devel­op­ment of poten­tial mol­e­cules from tril­lions of start­ing points. Valo’s approach aims to iden­ti­fy more impact­ful drug tar­gets and small mol­e­cule ther­a­peu­tics, faster, and with greater pre­ci­sion than tra­di­tion­al R&D meth­ods. The Com­pa­ny works with lead­ing glob­al phar­ma­ceu­ti­cal part­ners, includ­ing Novo Nordisk and Mer­ck KGaA, Darm­stadt, Ger­many, in addi­tion to advanc­ing its own pipeline. Valo was found­ed by Flag­ship Pio­neer­ing in 2019. Fol­low us on LinkedIn and X.

Media Con­tact:

Erin Smith
esmith@​valohealth.​com